MARKET

CELC

CELC

Celcuity Inc
NASDAQ
106.75
+2.47
+2.37%
After Hours: 108.24 +1.49 +1.40% 19:29 02/06 EST
OPEN
106.12
PREV CLOSE
104.28
HIGH
109.50
LOW
104.61
VOLUME
638.02K
TURNOVER
--
52 WEEK HIGH
120.32
52 WEEK LOW
7.58
MARKET CAP
4.94B
P/E (TTM)
-29.0793
1D
5D
1M
3M
1Y
5Y
1D
Director Sells 20,000 Celcuity Shares for $2.4 Million Following 933% Share Price Jump
NASDAQ · 1d ago
Celcuity präsentiert sich auf dem Guggenheim Emerging Outlook: Biotech Summit
Reuters · 3d ago
Xpeng, Serina Therapeutics, Dragonfly Energy Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Benzinga · 5d ago
Weekly Report: what happened at CELC last week (0126-0130)?
Weekly Report · 5d ago
Celcuity Inc. Director David Dalvey Reports Sale of Common Shares
Reuters · 01/29 21:32
Relay upgraded at Oppenheimer on optimism for zovegalisib
Seeking Alpha · 01/26 17:49
Weekly Report: what happened at CELC last week (0119-0123)?
Weekly Report · 01/26 09:05
Short Report: Celcuity short interest continues to grow
TipRanks · 01/25 18:40
More
About CELC
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.

Webull offers Celcuity Inc stock information, including NASDAQ: CELC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CELC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CELC stock methods without spending real money on the virtual paper trading platform.